Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Revolution Medicines Inc

RVMD
Current price
44.54 USD +0.75 USD (+1.71%)
Last closed 43.7 USD
ISIN US76155X1000
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 299 604 992 USD
Yield for 12 month +44.00 %
1Y
3Y
5Y
10Y
15Y
RVMD
21.11.2021 - 28.11.2021

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 700 Saginaw Drive, Redwood City, CA, United States, 94063

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

59.62 USD

P/E ratio

Dividend Yield

Current Year

+11 580 000 USD

Last Year

+35 380 000 USD

Current Quarter

Last Quarter

Current Year

+2 271 000 USD

Last Year

+25 724 000 USD

Current Quarter

-2 797 000 USD

Last Quarter

-2 763 000 USD

Key Figures RVMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -569 468 992 USD
Operating Margin TTM -77524.66 %
PE Ratio
Return On Assets TTM -24.95 %
PEG Ratio
Return On Equity TTM -40.73 %
Wall Street Target Price 59.62 USD
Revenue TTM 742 000 USD
Book Value 9.77 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -95.2 %
Dividend Yield
Gross Profit TTM -217 693 000 USD
Earnings per share -3.72 USD
Diluted Eps TTM -3.72 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics RVMD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History RVMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation RVMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7811.7221
Price Sales TTM 9837.742
Enterprise Value EBITDA -9.7077
Price Book MRQ 4.5091

Financials RVMD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators RVMD

For 52 weeks

15.44 USD 48.61 USD
50 Day MA 43.69 USD
Shares Short Prior Month 16 837 310
200 Day MA 35.25 USD
Short Ratio 17.4
Shares Short 16 505 419
Short Percent 10.53 %